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Abstract  23 
 24 
Rationale: Type-2-associated goblet cell hyperplasia and mucus hypersecretion are well known 25 
features of asthma. 15-Lipoxygenase (15LO1) is induced by the Type-2 cytokines/IL-13 in human 26 
airway epithelial cells (HAEC) in vitro and is increased in fresh asthmatic HAECs ex vivo. 15LO1 27 
generates a variety of products, including 15-hydroxyeicosatetraenoic acid (15-HETE), 15-HETE-28 
phosphatidyethanoloamine (PE) (15-HETE-PE) and 13-hydroxyoctadecadienoic acid (13-HODE). 29 
The current study investigated the 15LO1 metabolite profile at baseline and after IL-13 treatment, 30 
and the influence on goblet cell differentiation in HAECs. Methods: Primary HAECs obtained from 31 
bronchial brushings of asthmatic and healthy subjects were cultured under air-liquid interface (ALI) 32 
culture supplemented with arachidonic acid (AA) and linoleic acid (LA) (10 µM each) and exposed 33 
to IL-13 for 7 days. siRNA transfection and 15LO1 inhibition were applied to suppress 15LO1 34 
expression and activity. Results: IL-13 stimulation induced 15LO1 expression and preferentially 35 
generated 15-HETE-PE in vitro, both of which persist after removal of IL-13. 15LO1 inhibition 36 
(siRNA and chemical inhibitor) decreased IL-13 induced FOXA3 expression, while enhancing 37 
FOXA2 expression. These changes were associated with reductions in both MUC5AC and 38 
periostin. Exogenous 15-HETE-PE stimulation (alone) recapitulated IL-13 induced FOXA3, 39 
MUC5AC and periostin expression. Conclusions: The results from this study confirm the central 40 
importance of 15LO1 and its primary product 15-HETE-PE to epithelial cell remodeling in HAECs.  41 
 42 
Keywords: asthma, mucus hypersecretion, eicosanoid, 15-Lipoxygenase-1, phospholipid 43 
 44 
 45 
 46 
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Introduction 47 
 48 
Goblet cell hyperplasia and associated mucus hypersecretion are well known features of asthma 49 
which contribute to its morbidity and mortality. It is particularly seen in those patients with evidence 50 
for Type-2 (IL-4/-13) associated inflammation (1) (2, 3). This Type-2 process is believed to 51 
contribute to differentiation of basal epithelial cells into a goblet cell/mucus-producing epithelium. 52 
Previous studies further showed that MUC5AC was the major mucin increased in human airway 53 
epithelial cells (HAEC) in response to Type-2/IL-13 stimulation in vitro (4-10). Goblet cell 54 
differentiation appears to be tightly regulated by forkhead box protein transcription factors, 55 
including FOXA3 (for goblet cell differentiation) (11) and FOXA2 (associated with ciliated cell 56 
differentiation). FOXA3 is strongly upregulated by IL-13 (11, 12). However, the pathways by which 57 
IL-13 stimulates these downstream events are not known. 58 
Type-2 immunity impacts additional epithelial factors, including 15-lipoxygenase. As the only 59 
lipoxygenase class expressed by HAECs (13), 15-lipoxygenases (15LOX) catalyze oxygenation 60 
of polyunsaturated fatty acids, inserting molecular oxygen at the C15 position of arachidonic acid 61 
(AA) or the C13 position on linoleic acid (LA) to produce 15S-hydroxyeicosatetraenoic acid [15(S)- 62 
HETE (AA)], or 13S-hydroxyoctadecadienoic acid [13(S)-HODE) (LA)]. In humans, two distinct 63 
subtypes of 15LOX exist: 15LO1 (ALOX15) and 15LO2 (ALOX15B) with different tissue and 64 
cellular distribution (14-16) and possible differences in substrate preferences. While 15LO2 65 
exclusively oxygenates AA to generate 15(S)-HETE, with poor catalytic activity on LA (17), human 66 
reticulocyte 15LO1 has been reported to prefer LA in a cell-free system (18). 15LO1, and its 67 
product, 15-HETE are known to be elevated in asthmatic lungs, and upregulated by IL-4/-13 in 68 
vitro (10, 19, 20), while 15LO2 is not  (14, 19, 21).  Our studies also showed that IL-4/-13 induce 69 
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15LO1 expression associated with generation of 15-HETE conjugated with PE (15-HETE-PE) in 70 
both monocyte/macrophages and epithelial cells (10, 22).  This predisposition to 15-HETE-PE (as 71 
opposed to free 15-HETE) generation is seen in the presence of interactions with PEBP1, 72 
MAPK/ERK activation and MUC5AC expression (10, 23).  However, the balance of the LA or AA 73 
products,13-HODE, 15-HETE or their esterified forms, including 15-HETE-PE, as well as their 74 
contribution to cell differentiation and mucus hypersecretion in HAECs has not been evaluated.   75 
Finally, IL-13 is known to upregulate additional factors which associate with remodeling in the 76 
airway epithelium, including periostin which has been identified as a Type-2 biomarker in both 77 
HAECs and serum (24) (25). It is associated with matrix deposition and is likely part of a wound-78 
repair process, similar to mucin generation. 79 
We therefore hypothesized that 15LO1 would preferentially metabolize AA to generate 80 
phospholipid conjugated 15-HETE-PE, as opposed to free 15-HETE (or 13-HODE) in response to 81 
IL-13, which would regulate IL-13 induced goblet cell differentiation. To address this hypothesis, 82 
cultured HAECs stimulated with IL-13 and supplemented with AA/LA were evaluated for free and 83 
conjugated lipid products by LC/MS. The stability of 15LO1 expression and activity were evaluated 84 
as well as the effects of 15LO1 and its product 15-HETE-PE, on goblet cell differentiation and 85 
periostin expression (24) (25). 86 
 87 
 88 
 89 
 90 
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Materials and methods (Please see onlinesupplement for more complete methods) 91 
Reagents, antibodies and primers  92 
ALOX15 DsiRNATM was purchased from IDT (Coralville, IA). Antibodies against FOXA3 (goat IgG) 93 
and periostin (rabbit IgG1) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and 94 
anti-GAPDH antibody was from Novus Biologicals (Littleton, CO). Anti-MUC5AC antibody was 95 
from Neomarkers (Fremont, CA). 15LO1 antibody was a gift from Dr. Doug Conrad, University of 96 
California, San Diego(26). BLX2477, a highly specific inhibitor of 15LO1, was a kind gift from Dr. 97 
Hans-Erik Claesson (27). All other antibodies and reagents used are described in Online 98 
Supplement Materials and Methods. 99 
Sources of HAECs 100 
HAECs were obtained by bronchoscopic brushing of asthmatic and healthy control (HC) airways 101 
as previously described (28). See detail in Supplement Materials and Methods online. 102 
Primary Human Airway Epithelial Cell (HAEC) Culture in Air–Liquid Interface, DsiRNA 103 
Transfection and exogenous 15-HETE-PE stimulation 104 
HAECs were cultured in air–liquid interface (ALI) as previously described (23, 29), and DsiRNA 105 
transfection was performed using Lipofectamine transfection reagent, with details in Supplement 106 
Materials and Methods online. LA/AA supplementation and exogenous 15-HETE-PE stimulation 107 
were performed as described in Online Supplement Materials and Methods.   108 
15LO1 enzymatic inhibition with BLX2477  109 
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A selective enzymatic inhibitor of 15LO1 (BLX2477) was applied to IL-13 treated or untreated 110 
HAECs (27). BLX2477 (2 μM) was added acutely for 1 hour or up to 5 days before harvest (27). 111 
For longer duration studies, the culture medium and BLX2477 were changed every 24 hours. 112 
Liquid Chromatography/UV/Mass Spectrometry Analysis 113 
Cells were kept in PBS buffer containing diethylenetriaminepenta-acetic acid (DTPA) (100 μM) 114 
and butylated hydroxytoluene (BHT, 100 μM). Free and esterified HETEs were analyzed by LC/MS 115 
as previously described (30, 31).   116 
Western Blotting 117 
Cell lysates were run on 4-12% SDS-PAGE gels under reducing conditions and protein detected 118 
as previously described (32).   119 
Real-time PCR  120 
Real-time PCR was performed on the ABI Prism 7700 sequence detection system (Applied 121 
Biosystems) using primers and probes from Applied Biosystems, with GUSB as the internal control. 122 
An identical threshold cycle (Ct) was applied for each gene of interest. Relative mRNA expression 123 
levels were calculated using the delta Ct method. 124 
Semiquantitative MUC5AC ELISA   125 
MUC5AC protein was measured from apical culture supernatants using a semiquantitative 126 
sandwich ELISA with two different MUC5AC antibodies. All results are in relative arbitrary units 127 
per ml (AU/ml), and were reported as fold change in relative to corresponding control condition.  128 
See additional l details in Online Supplement Materials and Methods. 129 
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Statistical Analysis  130 
Statistical analysis was performed using JMP SAS software (Cary, NC). Data that were normally 131 
distributed were represented as means ± SEM. Each “n” identifies the number of biologically 132 
replicated experiments from different donors. For each donor condition, technical replicates were 133 
generally run in triplicate, except for western blots, which were done in singlets due to limitation of 134 
sample. Cells from asthmatic donors are identified by dashed lines, while HC donors are identified 135 
by solid lines. All comparisons of cells from specific donors, under 2 different conditions, i.e 136 
scramble and siALOX15, are run using paired T-test. P-values of <0.05 were considered 137 
statistically significant.    138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
 148 
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Results 149 
 150 
Demographics of research participants providing HAECs for culture 151 
Fresh human airway epithelial cells for ALI culture were obtained from a total of 44 subjects (Table 152 
S1). Due to the limited cell numbers and longer term development of the experimental models, 153 
donor sources for each experiment varied. However, as reported previously, studies of this 154 
pathway in vitro have not identified differences in response by subject group (asthma vs healthy 155 
control) (10, 22). Thus, cells from different subject groups were used interchangeably with subject 156 
group of donor cells identified on the figures: asthmatics and HCs shown by dashed and solid 157 
lines respectively.  There were no differences in response by age.     158 
 159 
15LO1 expression and specific enzymatic activity in HAECs 160 
IL-13 stimulation induces 15LO1 expression and preferentially increases 15-HETE-PE in the 161 
presence of equal LA/AA supplementation in vitro   162 
15LO1 has been reported to directly oxygenate endogenous PE to produce esterified 15-HETE-163 
PE in response to IL-13 stimulation. To determine whether 15LO1 generates additional lipid 164 
products in HAECs under IL-13 conditions, we stimulated HAECs with IL-13 for 7 days. 165 
Intracellular (cell lysates) and extracellular (medium) levels of 15-HETE-PE, 13-HODE-PE, 13-166 
HODE and 15-HETE were measured. To confirm that product specific generation was not 167 
dependent on intracellular depletion of LA and/or AA, culture media were supplemented with equal 168 
amounts (10 µM) of exogenous LA and AA under both basal and IL-13 conditions. As expected, 169 
IL-13 induced high levels of intracellular 15-HETE-PE (25.7±3.6 ng/million cells, 17.5±1.4 fold 170 
change over baseline, n=8, p<0.0001), with only modest increases in 13-HODE or free 15-HETE 171 
in cells under unsupplemented basal culture conditions (Figure 1a). Exogenous LA/AA 172 
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supplementation under basal conditions only modestly increased the overall levels of 15-HETE-173 
PE (23.3±4.1 ng/million cells),15-HETE (7.4±3.8 ng/million cells) and 13-HODE (8.9±4.3 ng/million 174 
cells) without alteration in their ratios to each other as compared to the unsupplemented basal 175 
condition ratios. In contrast, exogenous LA/AA supplementation of IL-13 stimulated cells 176 
generated marked increases in 15-HETE-PE (186.1±25 ng/million cells, 14.5±2.0 fold change over 177 
baseline, n=9, p<0.0001), with only modest increases in intracellular 13-HODE (9.8±2.3 ng/million 178 
cells, 1.9±0.3 fold change, n=9, p<0.02) and 15-HETE (8.7±1.6 ng/million cells, 1.6±0.2 fold 179 
change, n=6, NS) (Figure 1b). There were no differences in response by subject group under any 180 
conditions. Extracellular (media) 13-HODE and 15-HETE levels were both low at baseline and 181 
increased modestly in response to IL-13 (See supplemental Figure S1). As previously reported, 182 
no significant level of 15-HETE-PE was detected extracellularly with or without LA/AA 183 
supplementation (10, 22). Additionally, 13-HODE-PE was undetectable either extracellularly or 184 
intracellularly in any condition, with or without LA/AA supplementation. 185 
 186 
To determine whether the increase in 15-HETE-PE following IL-13 was associated with increased 187 
activity of 15LO1 or 15LO2, the levels of each protein were measured in IL-13 stimulated HAECs. 188 
As shown in Figure 1c, IL-13 markedly upregulated 15LO1 without effect on 15LO2. LA/AA 189 
supplementation did not impact 15LO1 and 15LO2 protein levels. 15LO1 protein was then 190 
knocked down by DsiRNA transfection (siALOX15) and 15-HETE-PE measured. Knockdown of 191 
15LO1 dramatically inhibited 15LO1 protein expression (Figure 1d, n=4) and 15-HETE-PE 192 
generation (n=11, p=0.001) (Figure 1e).  193 
 194 
To confirm the importance of 15LO1, the effect of a selective 15LO1 enzymatic inhibitor BLX2477 195 
was also studied. Primary HAECs were dosed with BLX2477 (2 µM) or vehicle control (DMSO) 196 
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for 1 hour for acute studies or every 24 hours up to 5 days to observe chronic effects. BLX2477 197 
decreased 15-HETE-PE generation as early as 1 hour after treatment (Figure 1f, n=8, p=0.023). 198 
Generation of 15-HETE-PE continued to be suppressed for up to 5 days of BLX2477 treatment 199 
(Figure 1g, n=3, p=0.041). Interestingly, 15LO1 protein (but not mRNA) was also suppressed by 200 
BLX2477 as compared to DMSO after 5 days treatment (Figure 1h, n=5, p=0.0002), suggesting a 201 
positive feedback mechanism through 15LO1 metabolites, but possibly also due to off-target 202 
effects of BLX2477 (27).    203 
 204 
15LO1 protein levels and activity persist in the absence of IL-13 205 
To determine the stability of IL-13 induced 15LO1 enzyme and activity, cells were stimulated with 206 
IL-13 for 7 days. IL-13 was then removed for the remaining culture period up to 72 hours. As 207 
shown in Figure 2a, IL-13 induced 15LO1 mRNA levels, which rapidly returned to basal levels 208 
after removal of IL-13. In contrast, high levels of 15LO1 protein remained for at least 72 hours 209 
following removal of IL-13 (Figure 2b). Additionally, intracellular 15-HETE-PE levels remained 210 
elevated over baseline after IL-13 removal (Figure 2c). These results suggest the sustained 211 
presence of an active enzyme in the absence of Type-2 stimulation for extended periods of time. 212 
 213 
15LO1 pathway and Epithelial Remodeling 214 
The 15LO1 pathway regulates IL-13 effects on FOXA3 and FOXA2 215 
To determine whether 15LO1 expression and activity were upstream of the Forkhead-box proteins 216 
FOXA3 and FOXA2 and central to goblet cell differentiation, DsiRNA 15LO1 knockdown was 217 
performed and FOXA3, FOXA2 and MUC5AC analyzed. Confirming previous work, FOXA3 218 
protein expression increased in a time dependent manner in ALI culture (supplemental FigureS2a). 219 
IL-13 induced high levels of FOXA3 mRNA and protein, which paralleled the increase of 15LO1 220 
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(supplemental Figure S2a, b). In contrast, FOXA2 mRNA was suppressed by IL-13 stimulation 221 
(supplemental Figure S2c). 15LO1 knockdown significantly decreased FOXA3 mRNA and protein 222 
expression (Figure 3a, b). As a marker of goblet cell differentiation, IL-13 induced MUC5AC 223 
expression was also suppressed by 15LO1 knockdown (Figure 3c, d). In contrast, 15LO1 224 
knockdown upregulated FOXA2 mRNA expression (Figure 3e). These results were confirmed 225 
utilizing the selective 15LO1 enzymatic inhibitor BLX2477 (Figure 4). Similar to the results with 226 
15LO1 knockdown, BLX2477 treatment significantly inhibited IL-13 induced FOXA3 mRNA 227 
(Figure 4a) and protein (Figure 4b). IL-13 induced MUC5AC mRNA (Figure 4c) and MUC5AC 228 
protein secretion (Figure 4d) were also inhibited by BLX2477 treatment. Similar to 15LO1 229 
knockdown, FOXA2 mRNA was upregulated by BLX2477 (Figure 4e).   230 
 231 
15LO1 pathway inhibition decreases periostin expression and secretion 232 
To determine whether 15LO1 expression and activity may be involved in other known Type-2 233 
pathways in HAECs, the impact of 15LO1 pathway inhibition on periostin was investigated. As 234 
expected, IL-13 induced both periostin mRNA (Figure S3a) and protein expression (Figure S3b) 235 
as well as secretion (Figure S3c). 15LO1 DsiRNA knockdown inhibited IL-13 induced periostin 236 
mRNA expression (Figure 5a) as well as intracellular (Figure 5b) and secreted periostin protein 237 
(Figure S4a). Similarly, BLX2477 (2 µM) treatment decreased periostin mRNA (Figure 5c) as well 238 
as intracellular (Figure 5d) and secreted protein (Figure S4b) after 5 days of exposure. Thus, the 239 
15LO1 pathway regulates a range of downstream Type-2 pathways beyond those related to goblet 240 
cell differentiation.  241 
 242 
Exogenous 15-HETE-PE stimulation induces FOXA3, MUC5AC and periostin expression in 243 
HAECs in the absence of IL-13 244 
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To determine whether products of an activated 15LO1 pathway, in the absence of IL-13, were 245 
sufficient to induce goblet cell differentiation and periostin expression, 1 μM 15-HETE-PE (or 246 
DMPE control) was added to HAECs in ALI every 48 hours up to 5 days. As shown in Figure 6, 247 
exogenous 15-HETE-PE induced FOXA3 (Figure 6a, b) as well as MUC5AC mRNA and protein 248 
expression (Figure 6c, d). Exogenous 15-HETE-PE stimulation also induced periostin mRNA and 249 
protein expression (Figure 6b, e). In contrast, there was no significant effect on FOXA2 (Figure 250 
6f). These data directly support both a necessary and sufficient role for 15-HETE-PE in regulation 251 
of goblet cell differentiation and periostin expression. However, under the specific conditions 252 
studied, the effects of exogenous 15HETE-PE were substantially more modest as compared to 253 
IL-13 stimulation.   254 
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Discussion 255 
The results from this study confirm the critical importance of 15LO1 and its primary product 15-256 
HETE-PE to epithelial cell remodeling associated with asthmatic airways. 15LO1 is the primary 257 
lipoxygenase induced in response to the Type-2 cytokine IL-13, and 15-HETE-PE is the primary 258 
product. Interestingly, this pathway remains present and active for extended periods of time 259 
despite removal of IL-13. Using knockdown, selective enzyme inhibitor and exogenous addition  260 
approaches, the results presented here confirm that the 15LO1 pathway regulates goblet cell  261 
differentiation, not only increasing expression of FOXA3, critical for goblet cell differentiation, but 262 
also preventing expression of pathways critical for ciliated cell formation (11, 33). Finally, 15LO1 263 
also impacts a broader range of Type-2/remodeling associated gene expression than just those 264 
associated with goblet cell differentiation, including a profound effect on periostin expression as 265 
well.    266 
 267 
Lipoxygenase enzymes can act on a variety of fatty acid substrates, commonly including AA and 268 
LA, to produce a range of oxygenated lipids. Human 15LO1, the most abundant lipoxygenase 269 
present in HAECs under TH2 conditions, has been reported to prefer LA over AA to generate 13-270 
HODEs using the competitive substrate capture method in a cell-free system (18). In HAECs, 271 
however, IL4/-13 preferentially increases (14, 19, 21)  a phospholipid (PE) conjugated form,   272 
15HETE-PE,  in both monocyte/macrophages and epithelial cells (10, 22). Our previous studies 273 
confirmed that IL-13 stimulated 15LO1 interacted with PEBP1 to further induce MAPK/ERK 274 
activation and MUC5AC expression (10, 23). This suggests that different lipid products of 15LO1 275 
pathway generated by specific substrate may play different biological roles in HAECs. However, 276 
it is unclear whether LA products, such at 13-HODE could also be playing a role. In the present 277 
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study, IL-13 stimulated HAECs supplemented with equal amounts of AA and LA, were evaluated 278 
for free and conjugated lipid products profiles by LC/MS. 279 
 280 
Lipoxygenases traditionally oxygenate free fatty acids, arachidonic acid originating predominantly 281 
from arachidonoyl-phospholipids following activation of phospholipases (34, 35). In the presence 282 
of free arachidonic acid (AA), this leads to the insertion of molecular oxygen at the C15 position 283 
and production of the unstable 15-hydroperoxy-eicosatetraenoic acid (15-HpETE), which is rapidly 284 
reduced to stable 15-HETE by one of glutathione peroxidases (eg, glutathione peroxidase 4 285 
(GPX4) (36, 37). However, unlike other lipoxygenases, 15LO1, under certain conditions, appears 286 
to alter its substrate preference from free AA to arachidonic acid containing phospholipids, 287 
resulting in high levels of 15-HETEs conjugated to phospholipids, particularly 15-HETE-PE (10, 288 
22, 30). In the present study, 15LO1 activity, under IL-13 conditions preferentially increases 15-289 
HETE-PE, with only minimal increases in free 15-HETE or 13-HODE with no detectable 13-HODE-290 
PE, despite previous studies suggesting LA is a preferred substrate in a cell-free system. This 291 
difference could be accounted for by the in vitro vs cell free systems, and the experimental 292 
conditions applied. Since our previous study showed that 15-HETE-PE regulates MAPK/ERK 293 
activation and MUC5AC expression in HAECs (10, 23), the disproportionate increase in 15-HETE-294 
PE suggests it plays a role in the goblet cell hyperplasia and mucus hypersecretion associated 295 
with asthma. At the same time, the robust increase in 15-HETE-PE in the presence of free AA 296 
further suggests that the AA is being incorporated into membrane phospholipids prior to being 297 
acted on by IL-13. Alternatively, 15LO1 may oxygenate free or esterified AA to produce 15-HpETE 298 
that is subsequently reacylated into lyso-PE.   299 
 300 
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15 LO1 has also been identified as an enzyme critical for generation of hydroperoxy-phospholipids, 301 
when 15LO1 switches from metabolizing free PUFAs to esterified AA-phospholipids (38). 302 
Generation of these intracellular esterified AA-phospholipids, particularly 15-HpETE could lead to 303 
a newly identified cell death termed ferroptosis (10, 30) (38). Thus, in addition to controlling cell 304 
differentiation, this switch to generation of 15-HpETE-PE (and 15-HETE-PE) could also control 305 
cell survival and death. However, the mechanisms by which 15LO1 changes its preference from 306 
free to phospholipid conjugated fatty acids, in particular AA, requires further study.    307 
 308 
Another important finding is the stability of 15LO1 protein and its enzyme activity. 15LO1 and its 309 
eicosanoid product 15-HETE have long been noted to be increased in human asthma in relation 310 
to severity and eosinophilic inflammation (14, 19, 39). 15LO1 is induced by Type-2 cytokines in 311 
monocytes/macrophages and in HAECs is one of the genes most strongly induced by IL-13 in 312 
vitro (20, 40, 41). Despite the very high expression of Type-2 signature genes like 15LO1, the 313 
levels of the presumed Type-2 cytokines, IL-4 and -13 (mRNA and protein) in asthmatics, 314 
especially those more severe patients treated with corticosteroids, are low (42, 43). The reasons 315 
for this disconnect between high levels of 15LO1 and low levels of Type-2 cytokines/IL-13 in vivo 316 
are not clear. However, the high, sustained 15LO1 protein levels and activity following removal of 317 
IL-13, as observed in this study, could contribute to prolonged IL-4/-13 downstream pathway 318 
activity, even in the absence of these cytokines. This long half-life appeared to be limited to protein, 319 
as mRNA levels fell rapidly. In contrast, high levels of 15LO1 protein remained for at least 72 hours 320 
following removal of IL-13. More importantly, intracellular 15-HETE-PE levels also remained 321 
elevated over baseline after IL-13 removal. Given that the media is changed every 2 days, this 322 
represents newly formed 15-HETE-PE. Thus, the enzyme is functional and contributing newly 323 
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formed lipid mediators long after removal of the IL-13, potentially explaining the high levels 324 
measured in vivo.  325 
We previously reported that 15LO1, conjugated with the scaffolding protein PEBP1, is critical for 326 
IL-13 induced HAEC MUC5AC expression. In addition, 15LO1 activity modulated eotaxin-327 
3/CCL26 and inducible NO synthase (23). However, its broader effects on Type-2 cytokine 328 
induced goblet cell differentiation/function are not known. Given its high levels and sustained 329 
activity, we hypothesized it would have a broad and central role. Recent studies have suggested 330 
that goblet cell differentiation is critically dependent on a specific forkhead DNA-binding protein 331 
(FOXA3) which binds to proximal promoters of several groups of genes associated with goblet cell 332 
metaplasia (11, 33) as well as suppression of FOXA2 (11, 12, 44). Both HAECs and transgenic 333 
mice studies confirmed FOXA3 induc d goblet cell metaplasia and enhanced expression of 334 
MUC5AC. Similarly, a recent microarray study of fresh HAECs from healthy and asthmatic 335 
subjects demonstrated high FOXA3 mRNA levels in Type-2 associated asthma, which correlated 336 
strongly with MUC5AC (and 15LO1) (39). In contrast, FOXA2 has been reported to suppress 337 
goblet cell metaplasia, while inducing ciliated cell differentiation (12). Interestingly, results 338 
presented here clearly show that expression and activity of the 15LO1 pathway, using chemical 339 
inhibitors, DsiRNA, and exogenous addition of 15-HETE-PE control IL-13 induced FOXA3. At the 340 
same time, FOXA2 expression was inhibited, supporting an overall effect of 15LO1 to influence 341 
remodeling of the airway epithelium in favor of goblet cells consistent with the microarray data (10, 342 
39). The lack of effect of exogenous 15-HETE-PE on FOXA2 expression requires further study, 343 
but may be related to both dose and uptake of the exogenous hydroxyl-phospholipid into the cells. 344 
The mechanisms by which 15LO1 expression/activity control the expression of these transcription 345 
factors remains speculative, but could include ERK/MAP kinase activation or interaction of 346 
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membrane phospholipids with the IL-4 receptor alpha or its downstream signaling pathways, 347 
including MEK-ERK.  Further study is needed.    348 
 349 
To begin to determine the extent to which 15LO1 controlled prominent IL-13 induced pathways, 350 
we also evaluated the impact of the 15LO1 pathway on HAEC periostin expression. Periostin is 351 
an extracellular matrix protein which can regulate adhesion and migration of epithelial cells in 352 
airway remodeling in asthma and other diseases (45, 46). Multiple studies report elevations in 353 
periostin mRNA in freshly brushed HAECs and serum from patients with Type-2 high asthma (24, 354 
25). Our results show that IL-13 induced high levels of periostin expression and secretion in 355 
HAECs consistent with previous studies. More importantly, our results show a marked inhibition 356 
of periostin expression in the face of 15LO1 inhibition which parallels the reductions in goblet cell 357 
differentiation as indicated by MUC5AC expression, and are mirrored by increases in periostin 358 
expression after exogenous 15-HETE-PE addition. These results suggest periostin expression is 359 
associated with goblet cell differentiation and mucus hypersecretion in response to IL-13 360 
stimulation in HAECs. Interestingly, in contrast to the findings reported here, periostin was recently 361 
suggested to suppress goblet cell metaplasia in a mouse model, with periostin knock-out mice 362 
demonstrating increased differentiation of epithelial cells into mucus-producing goblet cells upon 363 
sensitization and challenge with OVA without effect on allergic inflammation (47). Thus, in mice, 364 
an opposite effect for periostin on goblet cell metaplasia appears to be observed. Although the 365 
reasons for the differences in HAECs and in the mouse model are unclear, species-specific 366 
epithelial differences, the knockout models used, as well as the differences in the challenges could 367 
be explanations (47).   368 
 369 
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While the studies presented here strongly support development and testing of 15LO1 pathway 370 
inhibitors in asthma, replication of these findings in transgenic mice would add to the functional 371 
importance of the pathway. However, given the large differences between mouse and human 372 
airway epithelial cells and even structure, substantial studies to confirm the importance of this 373 
pathway in mice as compared to human airways will be required, including confirmation of whether 374 
mouse airway epithelial cells even express 15LO1, or the mouse equivalent 12/15LO1. Previous 375 
studies in transgenic mice have not commented on epithelial expression despite suppression of 376 
mucus (48).   377 
 378 
Summary and Conclusions 379 
The data presented here confirm a critical role for 15LO1 and its product 15-HETE-PE in HAEC 380 
goblet cell differentiation. Under IL-13 conditions, 15LO1 is the most abundant 15-lipoxygenase 381 
present in cultured HAECs, where it remains at high levels and active for prolonged periods of 382 
time even in the absence of IL-13. This IL-13 induced 15LO1 strongly favors the metabolism of 383 
arachidonic acid, conjugated with phospholipids over free fatty acids to form 15-HETE-PE, the 384 
process of which appears to be both necessary and sufficient to impact FOXA3 and periostin 385 
expression and goblet cell differentiation in vitro. Further studies are needed to better understand 386 
the mechanisms by which this pathway controls these epithelial changes, as well as functional 387 
implications of this pathway to human diseases like asthma.     388 
 389 
 390 
 391 
 392 
 393 
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Figure Legends 530 
Figure 1.  IL-13 stimulation induces 15LO1 expression and preferentially increases 15-HETE-PE 531 
in the presence of equal LA/AA supplement in vitro and is inhibited by DsiRNA transfection and 532 
chemical inhibition of 15LO1. HAECs were stimulated with IL-13 for 7 days with/without LA/AA 533 
supplements, and cell lysates collected for 15-HETE-PE, 13-HODE-PE, free 13-HODE and 15-534 
HETE measurement by LC/MS and 15LO1/2 protein detection by Western-blot. Solid lines: 535 
healthy controls; Dashed lines: asthmatics. (a) IL-13 induced high levels of intracellular 15-536 
HETE-PE, with only modest increases in 13-HODE and free 15-HETE under basal conditions 537 
without exogenous LA/AA supplementation. (b) supplementation with LA/AA further increased 538 
IL-13 induced generation of 15-HETE-PE, with only modest increases in 13-HODE and 15-539 
HETE. No 13-HODE-PE was detected. (c) Representative western-blot and densitometry (n=3) 540 
show IL-13 induced 15LO1 expression without effect on 15LO2, and LA/AA supplementation did 541 
not impact 15LO1 and 15LO2 protein levels.  (d) DsiRNA knockdown of 15LO1 inhibited 15LO1 542 
protein expression (n =4) and (e) 15-HETE-PE generation.  The selective 15LO1 enzymatic 543 
inhibitor BLX2477 suppressed 15-HETE-PE generation at 1 hour (f) and 5 days of treatment (g), 544 
and (h) BLX2477 suppressed 15LO1 protein expression at 5 days of treatment.      545 
Figure 2. IL-13 induced 15LO1 and 15-HETE-PE remain stable after the removal of IL-13. 546 
HAECs were all stimulated with IL-13 for 7 days except the control condition.  IL-13 was 547 
removed for the remaining culture period up to 72 hours. Cell lysates were collected for 15-548 
HETE-PE by LC/MS and 15LO1 expression by Real-time PCR and Western-blot. (a) IL-13 549 
induced 15LO1 mRNA levels rapidly return to basal levels at 24 hours after removal of IL-13. (b) 550 
high levels of 15LO1 protein remain for at least 72 hours following removal of IL-13. (c) 551 
intracellular 15-HETE-PE levels remain elevated over baseline after IL-13 removal.  552 
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Figure 3. 15LO1 knockdown suppresses IL-13 induced FOXA3 and MUC5AC while increasing 553 
FOXA2 expression.  HAECs with/without 15LO1 siRNA (siALOX15) transfections were 554 
stimulated with IL-13 for 7 days, and cell lysates collected for protein and mRNA analysis. (a) 555 
15LO1 knockdown suppressed IL-13 induced FOXA3 mRNA and (b) protein expression 556 
(representative Western-blot and densitometry, n=4). (c) 15LO1 knockdown suppressed 557 
MUC5AC mRNA and (d) protein expression induced by IL-13 (measured by ELISA, shown as 558 
fold change related to scramble control).  (e) 15LO1 knockdown upregulated FOXA2 mRNA.  559 
Figure 4. BLX2477 treatment inhibited IL-13 induced FOXA3 and MUC5AC while increasing 560 
FOXA2 expression.  HAECs stimulated with IL-13 for 7 days were treated with BLX2477 at 2 µM 561 
for 5 days with DMSO as the vehicle control, and cell lysates collected for mRNA and protein 562 
analysis. (a) BLX2477 decreased FOXA3 mRNA and (b) protein expression induced by IL-13. 563 
(c) BLX2477 suppressed MUC5AC mRNA and (d) protein expression (measured by ELISA, 564 
shown as fold change related to DMSO control) induced by IL-13. (e) BLX2477 increased 565 
FOXA2 mRNA in response to IL-13 stimulation.   566 
Figure 5. Suppression of 15LO1 levels and activity decreased IL-13 induced periostin 567 
expression. HAECs stimulated with IL-13 were transfected with DsiRNA or treated with 568 
BLX2477, and cell lysates collected for mRNA and protein analysis. 15LO1 knockdown (a, b) 569 
and BLX2477 treatment (c, d) both suppressed IL-13 induced perisotin mRNA and protein 570 
expression.   571 
Figure 6. Exogenous 15-HETE-PE stimulation induced FOXA3, MUC5AC and periostin 572 
expression in HAECs in the absence of IL-13. HAECs under ALI culture were stimulated with 1 573 
μM 15HETE-PE for 5 days, with DMPE applied as vehicle control. 15-HETE-PE induced FOXA3 574 
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(a, b), MUC5AC (c, d) and periostin (b, e), while no effect on FOXA2 (f).  Data presented as means 575 
± SEM, analyzed by paired T-test.  576 
  577 
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Figure 6
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Preferential generation of 15-HETE-PE induced by IL-13 regulates goblet cell 1 
differentiation in human airway epithelial cells 2 
Online Supplement 3 
Materials and methods  4 
Reagents, antibodies and primers  5 
ALOX15 DsiRNATM was purchased from IDT (Coralville, IA), and Lepofectamine transfection 6 
reagent was from Thermo Fisher (Rodkford, IL). Antibodies against FOXA3 (goat IgG) and 7 
periostin (rabbit IgG1) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-8 
GAPDH antibody was from Novus Biologicals (Littleton, CO). Anti-MUC5AC antibody was from 9 
Neomarkers (Fremont, CA). Basic Epithelial Growth Medium (BEGM) cell culture medium and 10 
supplements are purchased from Lonza (Bas l, Switzerland). Recombinant human IL-13 was 11 
purchased from R&D Systems (Minneapolis, MN). AA and LA were from Cayman Inc (Ann Arbor, 12 
Michigan). 15LO1 antibody was a gift from Dr. Doug Conrad, University of California, San Diego(1). 13 
15LO2 antibody was purchased from Abcam (Cambridge, MA). Real-Time PCR primers and 14 
probes were all purchased from Applied Biosystems (Foster City, CA). BLX2477, a highly specific 15 
inhibitor of 15LO1, was a kind gift from Dr. Hans-Erik Claesson (2).   16 
Sources of HAECs 17 
HAECs were obtained by bronchoscopic brushing of asthmatic and healthy control (HC) airways 18 
as previously described (3). All participants were recruited as part of the National Heart, Lung, and 19 
Blood Institute’s Severe Asthma Research Program or the Electrophilic Fatty Acid Derivatives in 20 
Asthma studies (4). All asthmatic participants met American Thoracic Society (ATS) criteria for 21 
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asthma and included mild to severe asthmatic patients, while HCs were without respiratory 22 
disease and had normal lung function (5, 6). No subject smoked within the last year or >5 pack 23 
years. The study was approved by the University of Pittsburgh Institutional Review Board and all 24 
participants gave informed consent.   25 
Primary Human Airway Epithelial Cell (HAEC) Culture in Air–Liquid Interface, DsiRNA 26 
Transfection and exogenous 15-HETE-PE stimulation 27 
HAECs were cultured in air–liquid interface (ALI) under serum-free condition as previously 28 
described (5, 7). Briefly, fresh bronchoscopic brushing primary HAECs were cultured under 29 
immersed condition for proliferation. When 80-90% confluent, cells are trypsinized and plated at 30 
5 x 104 cells per well on 12-well Transwell plate for submerged stage culture by adding 200 μl 31 
culture mdium to upper insert and 1000 μl culture medium to lower chamber [BEBM/DMEM at 32 
50:50, supplemetal with 4 g/ml Insulin, 5 pg/ml Transferrin, 0.5 µg/ml Hydrocortisone, 0.5 µg/ml 33 
Epinephrine, 52 µg/ml Bovine hypothalamus extract, 50 µg/ml Gentamicin, 50 ng/ml Amphotericin, 34 
0.5 µg/ml albumine bovine, 80nM ethanolamine, 0.3 mM MgCl2, 0.4 mM MgSO4, 1 mM CaCl2, 35 
30 ng/ml retinoic acid and 0.5 ng/ml Epithelial Growth Factor (EGF)]. When cells reached 100% 36 
confluence, cells went into ALI culture for by reducing the upper volume to 50 µl with the lower 37 
volume remaining at 1.0 mL full medium.  38 
DsiRNA transfection was performed using Lipofectamine transfection reagent. Briefly, 50 nM 39 
DsiRNA was pre-mixed with 3 μl/well Lipofectamine transfection reagent for 20 minutes at room 40 
temperature before pooled together with HAECs suspension and seeded onto transwells for 41 
incubations. After 24 hours, the transfection mixture was removed and cells were switched to ALI 42 
culture for 7 days.  Cells were stimulated with IL-13 (10 ng/ml) under ALI culture for 7 days unless 43 
specified otherwise. For LA/AA supplementation, equal amounts of exogenous 10 µM LA and 10 44 
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µM AA were added into the basal culture medium for three days before harvest. For exogenous 45 
15-HETE-PE stimulation, 1 μM 15-HETE-PE [HPLC/MS collection dissolved in methanol as 46 
previously described (10)] was added into medium for culture for 5 days, with DMPE (Dimyristoyl-47 
phosphoethanolamine) dissolved in methanol applied as vehicle control.   48 
Semiquantitative MUC5AC ELISA   49 
MUC5AC protein was measured from apical culture supernatants using a semiquantitative 50 
sandwich ELISA with two different MUC5AC antibodies, one for coating and one for detection. 51 
Briefly, high binding plates were coated with Neomarkers (Fremont, CA) MUC5AC antibody (1-52 
13M1) at 1 μg/ml.  Neomarker MUC5AC antibody (45M1) labeled with biotin was used at 0.2-0.4 53 
μg/ml for detection. The MUC5AC standard was generated from the apical supernatants of IL-13 54 
stimulated HAECs cells under ALI and diluted 1/100 for the high standard followed by serial half-55 
dilution. Thus, all results are in relative arbitrary units per ml (AU/ml) and semi-quantitative. 56 
Samples were studied without dilution or up to 1/4000 dilution depending on sample/system. Thus, 57 
the MUC5AC results were reported as fold change in relative to corresponding control condition. 58 
 59 
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Supplement Figure Legends 97 
Figure S1.  IL-13 stimulation induces modest increases in free 15-HETE and 13-HODE in cell 98 
culture media in the presence of equal LA/AA supplement in HAECs. HAECs were stimulated 99 
with IL-13 for 7 days with LA/AA supplements, and culture media collected for 13-HODE and 15-100 
HETE measurement by LC/MS. 101 
Figure S2. IL-13 induced FOXA3 expression while downregulating FOXA2 mRNA expression. 102 
HAECs were stimulated with IL-13 for 3 to 7 days, and cell lysates collected for protein and 103 
mRNA analysis. IL-13 induced FOXA3 expression which paralleled the increase of 15LO1 (a, b), 104 
while suppressed FOXA2 expression (c).   105 
Figure S3. IL-13 induced periostin (a) mRNA, (b) protein expression and (c) secretion. HAECs 106 
were stimulated with IL-13 for 7 days, and cell lysates and lower chamber culture media 107 
collected for mRNA and protein detection. For Western-blot in Figure S3c, 50 μl of culture media 108 
was loaded in each sample.   109 
Figure S4.   15LO1 suppression decreases periostin secretion induced by IL-13 in HAECs. HAECs 110 
with IL-13 stimulation were transfected with DsiRNA or treated with BLX2477, and culture media 111 
collected for protein detection. 15LO1 knockdown (a) and BLX2447 treatment (b) suppressed 112 
perisotin secretion induced by IL-13. 50 μl of culture media was loaded in each sample.   113 
 114 
 115 
 116 
 117 
 118 
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Healthy Mild/Moderate Severe
n=18 n=16 n=10
Gender (M/F) 5/13 5/11 4/6
Age (year), median ± SE 30.5 ± 2.9 29 ± 3.6 49 ± 1.6
Race (C/AA/O) 17/0/1 6/10/0 7/2/1
FeNO (ppb), median ± SE 12 ± 1.7 17 ± 6.1 41 ± 9.6
FEV1 (%predicted), median ± SE 102 ± 1.5 92 ± 3.5 79 ± 5.8
ICS (yes/no) NA 11/5 10/0
Table S1
Definition of abbreviations: FeNO = Fractional exhaled nitric oxide; 
ICS = Inhaled corticosteroid; M/F = Male/Female; C/AA/O = Caucasian/African American/Others; 
NA = Not applicable
Demographics of research participants providing HAECs for culture
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Figure S2
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Figure S3
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Figure S4
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